RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Get ready for more merger mania in the pharma sector Furthermore, ONCY's pelareorep is not "time-bound" since the UDFDA has provided 12 years of marketing exclusivity for a biologic like ONCY's pelareorep, beginning at the time of marketing approval for each indication in which a BLA has been submitted, and this exclusivity is over and above a patent and it expiry date. This also means that if another agent nearing its patent expiration is effectively combined with pelareorep, and this combination is successful is approved by the FDA as a combined therapy, then this combination would receive 12 years of market exclusivity notwithstanding each product's patent status. In contrast mining and oil/gas companies are "time-bound" with a finite defined value and have nothing in common with the way next generation biotech companies with innovative immuno-oncology biologics are valued.